𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activity of sirolimus in patients with myelodysplastic syndrome – results of a pilot study

✍ Scribed by U. Platzbecker; M. Haase; R. Herbst; A. Hänel; K. Voigtmann; C. H. Thiede; B. Mohr; E. Schleyer; T. Leopold; M. Orth; M. Hänel; G. Ehninger; M. Bornhäuser

Book ID
108673053
Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
98 KB
Volume
128
Category
Article
ISSN
0007-1048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Decitabine improves patient outcomes in
Decitabine improves patient outcomes in myelodysplastic syndromes : Results of a phase III randomized study
✍ Hagop Kantarjian; Jean-Pierre J. Issa; Craig S. Rosenfeld; John M. Bennett; Mahe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB

## Abstract ## BACKGROUND Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters.

The clinical significance of activated l
The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients
✍ Stef Meers; Peter Vandenberghe; Marc Boogaerts; Gregor Verhoef; Michel Delforge 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 457 KB

We studied the immune compartment in patients with myelodysplastic syndromes. We show increased surface expression of activation markers (HLA-DR(+), CD57(+), CD28(-), CD62L(-)) on T lymphocytes in blood and bone marrow (n=131). T cell activation was not restricted to any relevant clinical subgroup (